SONOVAL LLC

Gaithersburg, MD · Biotech · Defunct

Biologic cancer immunotherapies (SON-211, SON-301) that deplete regulatory T cells to enhance anti-tumor immunity

Grants
$5.1M
5 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Treg-depleting immunotherapy$250,548
Federal grantDepartment of Health and Human Services · Phase II · Treg-depleting immunotherapy$2,000,000
Federal grantDepartment of Health and Human Services · Phase II · Treg-depleting immunotherapy$811,405
Federal grantDepartment of Health and Human Services · Phase II · Immunotherapy to deplete key Treg subsets in solid tumors$1,293,505
Federal grantDepartment of Health and Human Services · Phase II · Immunotherapy to deplete key Treg subsets in solid tumors$706,495
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3228ROCKLAND IMMUNOCHEMICALS, INC.——
3229GATACA, LLC——
3230KADVAX TECHNOLOGIES, INC.——
3231SONOVAL LLC——
3232ROSEBUD BIOSCIENCES INC.——
3233Therapeutic Vision, Inc.——
3234Florica Therapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.